Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Natera Inc
(NQ:
NTRA
)
123.98
+1.73 (+1.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Natera Inc
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
9 Health Care Stocks Whale Activity In Today's Session
March 08, 2024
Via
Benzinga
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
March 07, 2024
From
Natera, Inc.
Via
Business Wire
Agilent Technologies Stock Getting Closer To Key Technical Benchmark
March 05, 2024
Agilent Technologies stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 65 to 71.
Via
Investor's Business Daily
Wall Street Takes A Breather As Inflation Stays Tamed, AMD Hits Record Highs, Apple Struggles: What's Driving Markets Thursday?
February 29, 2024
Wall Street exhaled a sigh of relief as the Federal Reserve’s favored gauge of inflation cooled as anticipated in January, quelling fears that an unexpected rise in the Consumer Price Index (CPI) might...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Natera to Participate in March Investor Conferences
February 29, 2024
From
Natera, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 28, 2024
Via
Benzinga
Recap: Natera Q4 Earnings
February 28, 2024
Via
Benzinga
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
February 28, 2024
From
Natera, Inc.
Via
Business Wire
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
February 27, 2024
On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades.
Via
Benzinga
Earnings Preview For Natera
February 27, 2024
Via
Benzinga
A Glimpse Into The Expert Outlook On Natera Through 9 Analysts
February 20, 2024
Via
Benzinga
Earnings Scheduled For February 28, 2024
February 28, 2024
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
Via
Benzinga
There are signs that NASDAQ:NTRA may be ready to breakout.
February 16, 2024
NATERA INC (NASDAQ:NTRA) has a good technical rating of 10 out of 10 and could possibly break out.
Via
Chartmill
Expert Ratings For Natera
January 17, 2024
Via
Benzinga
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
February 27, 2024
From
Natera, Inc.
Via
Business Wire
Medicare Extends Coverage of Natera’s Signatera™ MRD Test to Ovarian Cancer and Neoadjuvant Breast Cancer
February 26, 2024
From
Natera, Inc.
Via
Business Wire
Natera Announces Fourth Quarter and Fiscal 2023 Earnings Conference Call
February 20, 2024
From
Natera, Inc.
Via
Business Wire
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
February 06, 2024
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
Via
InvestorPlace
NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy
February 06, 2024
NVTA stock tumbled yesterday amid a report that the firm could declare bankruptcy soon. The shares were halted for news pending.
Via
InvestorPlace
Topics
Bankruptcy
Exposures
Financial
Legal
SoftBank-Backed Genetic Testing Invitae's Descent from $7B Valuation to Near-Bankruptcy
February 05, 2024
Invitae's financial challenges as it grapples with a $1.5 billion debt burden. Explore the company's strategic options amidst potential bankruptcy, asset shedding, and cost-cutting measures.
Via
Benzinga
Topics
Bankruptcy
Exposures
Financial
Legal
Pinterest, Checkpoint Therapeutics And 2 Other Stocks Insiders Are Selling
February 05, 2024
The Nasdaq 100 closed higher by around 300 points on Friday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
New Study Validates Signatera™ in Endometrial Cancer
February 05, 2024
From
Natera, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END
Via
FinancialNewsMedia
New Publication Demonstrates Signatera’s Ability to Risk Stratify and Detect Recurrence Early in Resected Stage I-II Lung Cancer
January 30, 2024
From
Natera, Inc.
Via
Business Wire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
January 30, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Jury Rules in Favor of Natera in Patent Infringement Lawsuit Against CareDx; Awards $96.3 Million in Damages to Natera in Lost Profits and Past Royalties
January 29, 2024
From
Natera, Inc.
Via
Business Wire
Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
January 25, 2024
From
Natera, Inc.
Via
Business Wire
Natera Acquires Reproductive Health Assets from Invitae
January 22, 2024
From
Natera, Inc.
Via
Business Wire
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
January 18, 2024
From
Natera, Inc.
Via
Business Wire
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle
January 17, 2024
The company must pay $57 million in damages, but that's far less than expected.
Via
Investor's Business Daily
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.